最新消息

Thailand: Thai FDA Announcement: Exemption of Prescribed Information, Documents, and Evidence for Licensed and Notified Medical Devices, 2024 - August/September 2024

Thailand: Thai FDA Announcement: Exemption of Prescribed Information, Documents, and Evidence for Licensed and Notified Medical Devices, 2024 - August/September 2024

  • 2024-09-17 02:22:43

The Thai FDA has announced significant regulatory changes to accelerate the approval process for medical device manufacturing and importation. Effective June 6, 2024, these changes aim to reduce redundancy in documentation without compromising product safety or quality. This streamlined approach is expected to foster innovation, attract foreign investment, and enhance Thailand's position as a regional healthcare hub.

了解更多
AUSTRALIA: Use of Market Authorisation Evidence from Comparable Overseas Regulators / Assessment Bodies for Medical Devices (including IVDs) - October/November 2022

AUSTRALIA: Use of Market Authorisation Evidence from Comparable Overseas Regulators / Assessment Bodies for Medical Devices (including IVDs) - October/November 2022

  • 2022-10-25 07:32:01

In Australia, the “Use of market authorisation evidence from comparable overseas regulators / assessment bodies for medical devices (including IVDs)” and the “Reduction of Assessment Fees for Medical Devices Guideline”, both outline specific situations in which the assessment procedures and the assessment costs for medical devices may be reduced.
The guideline provides details on the criteria and the eligibility for TGA to determine whether the process can be reduced for application audit assessments and conformity assessments involving medical devices (including IVDs).

了解更多
AUSTRALIA: Clinical Evidence Guidelines: Medical Devices – July 2022

AUSTRALIA: Clinical Evidence Guidelines: Medical Devices – July 2022

  • 2022-07-26 09:41:26

The TGA has released version 3.1 of its latest guideline for the clinical evidence for medical devices. The purpose of this guideline is to allow both industry and TGA to support sponsors and manufacturers to collect, compile and present clinical evidence under regulatory requirements as well as to inform on how TGA assesses clinical evidence.

了解更多
AUSTRALIA: TGA Evidence Expectations for Medical Devices or Surfaces with Anti-Viral or Anti-Microbial Claims – June 2022

AUSTRALIA: TGA Evidence Expectations for Medical Devices or Surfaces with Anti-Viral or Anti-Microbial Claims – June 2022

  • 2022-06-29 01:41:00

The TGA has given a presentation about the evidence expectations for medical devices or surfaces with anti-viral or anti-microbial claims in the Australasian Society for Biomaterials and Tissue Engineering (ASBTE) Conference 2022. This presentation provided manufacturers and sponsors general insights on the subject of medical devices with anti-viral or anti-microbial claims before the device inclusion in the Australian Register of Therapeutic Goods (ARTG).

了解更多